Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/CHEBI_73274
http://purl.obolibrary.org/obo/CHEBI_73274
|
|---|---|
| Preferred Name | canagliflozin |
| Synonyms |
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol
C24H25FO5S
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | canagliflozin
|
|---|---|
| label | canagliflozin
|
| DBSynonym | canagliflozin hydrate
|
| ATCCode | A10BX11
|
| Definition | A C-glycosyl compound that is used (in its hemihydrate form) for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2.
Canagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered. FDA approved on March 29, 2013.
|
| has pharmacological target | |
| inhibits | |
| type | |
| has role | |
| InChIKey | InChIKey=XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
|
| is metabolised by | |
| AHFScode | 68:20.18
|
| Synonym | (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol
C24H25FO5S
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
|
| xref |
RxList:http://www.rxlist.com/invokana-drug.htm
Wikipedia:Canagliflozin
CiteXplore:23564919
CiteXplore:23590413
ChEMBL:1451917
CiteXplore:22492586
CiteXplore:22548646
CiteXplore:22226086
National Drug Code Directory:50458-141-30
CiteXplore:22385274
Wikipedia:http://en.wikipedia.org/wiki/Canagliflozin
Reaxys:18362681
CiteXplore:23087012
CiteXplore:23370138
Patent:WO2011142478
CiteXplore:23464594
CiteXplore:22621689
Patent:US2010099883
CiteXplore:21457428
CASRN:842133-18-0
CiteXplore:20690635
Patent:US2012289694
CiteXplore:23412078
ChEBI:73274
CiteXplore:22355316
Patent:WO2009035969
CiteXplore:23585665
CiteXplore:23279307
CiteXplore:22632452
Patent:US2008146515
CiteXplore:23563279
Drugs.com:http://www.drugs.com/invokana.html
See more
See less
|
| CASRN | 842133-18-0
|
| prefixIRI | obo2:CHEBI_73274
|
| is transported by | |
| is substrate of | |
| SMILES |
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)c1ccc(C)c(Cc2ccc(s2)-c2ccc(F)cc2)c1
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
|
| may interact with | |
| InChI | InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
|
| DBBrand | invokana
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |